← Back to Clinical Trials
Recruiting NCT06420999

Incidence and Impact of ICU-acquired Diaphragm Weakness

Trial Parameters

Condition Diaphragm Dysfunction
Sponsor Assistance Publique - Hôpitaux de Paris
Study Type OBSERVATIONAL
Phase N/A
Enrollment 194
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-07-29
Completion 2028-01-29
Interventions
Diaphragmatic ultrasound and data collection

Brief Summary

ICU survivors are at an increased risk of hospital and ICU readmission. Among the complications of ICU stay, diaphragmatic dysfunction is common, with a prevalence of 60 to 80%, and is associated with increased mortality and prolonged hospital stays. Furthermore, several studies have reported that the observation of impaired respiratory muscle function upon ICU discharge is associated with a poor long-term prognosis. However, the incidence and prognostic impact of persistent diaphragmatic dysfunction at ICU discharge have never been evaluated. The measurement of dyspnea, a composite evaluation of respiratory muscle function, has not been assessed for predicting prognosis upon ICU discharge. The hypothesis of the project is that the presence of ICU-acquired diaphragmatic dysfunction at ICU discharge is associated with a poorer prognosis within 90 days.

Eligibility Criteria

Inclusion Criteria: 1. Age ≥ 18 years 2. Invasive or non-invasive respiratory support (ventilation, high-flow oxygen therapy, whatever the reason) for at least 48 hours. 3. Weaning from respiratory support (invasive or not) within the last 24 hours. 4. Patient (or trusted person/relative) informed and not opposed to the study. Exclusion Criteria: 1. Known pre-existing diaphragmatic dysfunction (phrenic lesion, neuromuscular disease, etc.) 2. Patients with tracheostomy 3. Non-communicating patients 4. Patients deprived of liberty by court or administrative order, or under legal protection (guardianship, curators).

Related Trials